Literature DB >> 27133167

Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans.

Tommi Vatanen1, Aleksandar D Kostic2, Eva d'Hennezel3, Heli Siljander4, Eric A Franzosa5, Moran Yassour6, Raivo Kolde7, Hera Vlamakis6, Timothy D Arthur6, Anu-Maaria Hämäläinen8, Aleksandr Peet9, Vallo Tillmann9, Raivo Uibo10, Sergei Mokurov11, Natalya Dorshakova12, Jorma Ilonen13, Suvi M Virtanen14, Susanne J Szabo3, Jeffrey A Porter3, Harri Lähdesmäki15, Curtis Huttenhower5, Dirk Gevers6, Thomas W Cullen3, Mikael Knip16, Ramnik J Xavier17.   

Abstract

According to the hygiene hypothesis, the increasing incidence of autoimmune diseases in western countries may be explained by changes in early microbial exposure, leading to altered immune maturation. We followed gut microbiome development from birth until age three in 222 infants in Northern Europe, where early-onset autoimmune diseases are common in Finland and Estonia but are less prevalent in Russia. We found that Bacteroides species are lowly abundant in Russians but dominate in Finnish and Estonian infants. Therefore, their lipopolysaccharide (LPS) exposures arose primarily from Bacteroides rather than from Escherichia coli, which is a potent innate immune activator. We show that Bacteroides LPS is structurally distinct from E. coli LPS and inhibits innate immune signaling and endotoxin tolerance; furthermore, unlike LPS from E. coli, B. dorei LPS does not decrease incidence of autoimmune diabetes in non-obese diabetic mice. Early colonization by immunologically silencing microbiota may thus preclude aspects of immune education.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27133167      PMCID: PMC4950857          DOI: 10.1016/j.cell.2016.04.007

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  43 in total

1.  Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2.

Authors:  M Hirschfeld; Y Ma; J H Weis; S N Vogel; J J Weis
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

2.  Human Toll-like receptor 4 recognizes host-specific LPS modifications.

Authors:  Adeline M Hajjar; Robert K Ernst; Jeff H Tsai; Christopher B Wilson; Samuel I Miller
Journal:  Nat Immunol       Date:  2002-03-25       Impact factor: 25.606

3.  Bacteroides in the infant gut consume milk oligosaccharides via mucus-utilization pathways.

Authors:  Angela Marcobal; Mariana Barboza; Erica D Sonnenburg; Nicholas Pudlo; Eric C Martens; Prerak Desai; Carlito B Lebrilla; Bart C Weimer; David A Mills; J Bruce German; Justin L Sonnenburg
Journal:  Cell Host Microbe       Date:  2011-10-27       Impact factor: 21.023

4.  Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity.

Authors:  Janet G M Markle; Daniel N Frank; Steven Mortin-Toth; Charles E Robertson; Leah M Feazel; Ulrike Rolle-Kampczyk; Martin von Bergen; Kathy D McCoy; Andrew J Macpherson; Jayne S Danska
Journal:  Science       Date:  2013-01-17       Impact factor: 47.728

5.  Lower economic status and inferior hygienic environment may protect against celiac disease.

Authors:  Anita Kondrashova; Kirsi Mustalahti; Katri Kaukinen; Hanna Viskari; Vera Volodicheva; Anna-Maija Haapala; Jorma Ilonen; Mikael Knip; Markku Mäki; Heikki Hyöty
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

6.  The genome sequence of Bifidobacterium longum subsp. infantis reveals adaptations for milk utilization within the infant microbiome.

Authors:  D A Sela; J Chapman; A Adeuya; J H Kim; F Chen; T R Whitehead; A Lapidus; D S Rokhsar; C B Lebrilla; J B German; N P Price; P M Richardson; D A Mills
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-24       Impact factor: 11.205

7.  Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment.

Authors:  Xochitl C Morgan; Timothy L Tickle; Harry Sokol; Dirk Gevers; Kathryn L Devaney; Doyle V Ward; Joshua A Reyes; Samir A Shah; Neal LeLeiko; Scott B Snapper; Athos Bousvaros; Joshua Korzenik; Bruce E Sands; Ramnik J Xavier; Curtis Huttenhower
Journal:  Genome Biol       Date:  2012-04-16       Impact factor: 13.583

8.  Characterization of the diversity and temporal stability of bacterial communities in human milk.

Authors:  Katherine M Hunt; James A Foster; Larry J Forney; Ursel M E Schütte; Daniel L Beck; Zaid Abdo; Lawrence K Fox; Janet E Williams; Michelle K McGuire; Mark A McGuire
Journal:  PLoS One       Date:  2011-06-17       Impact factor: 3.240

9.  Innate immunity and intestinal microbiota in the development of Type 1 diabetes.

Authors:  Li Wen; Ruth E Ley; Pavel Yu Volchkov; Peter B Stranges; Lia Avanesyan; Austin C Stonebraker; Changyun Hu; F Susan Wong; Gregory L Szot; Jeffrey A Bluestone; Jeffrey I Gordon; Alexander V Chervonsky
Journal:  Nature       Date:  2008-09-21       Impact factor: 49.962

10.  MODIFICATION OF HOST RESPONSES TO BACTERIAL ENDOTOXINS. I. SPECIFICITY OF PYROGENIC TOLERANCE AND THE ROLE OF HYPERSENSITIVITY IN PYROGENICITY, LETHALITY, AND SKIN REACTIVITY.

Authors:  D W WATSON; Y B KIM
Journal:  J Exp Med       Date:  1963-09-01       Impact factor: 14.307

View more
  345 in total

1.  Uncovering a Shared Epitope-Activated Protein Citrullination Pathway.

Authors:  Vincent van Drongelen; Wahida H Ali; Joseph Holoshitz
Journal:  J Immunol       Date:  2020-06-26       Impact factor: 5.422

Review 2.  Dysbiosis and the immune system.

Authors:  Maayan Levy; Aleksandra A Kolodziejczyk; Christoph A Thaiss; Eran Elinav
Journal:  Nat Rev Immunol       Date:  2017-03-06       Impact factor: 53.106

Review 3.  Regulation of inflammation by microbiota interactions with the host.

Authors:  J Magarian Blander; Randy S Longman; Iliyan D Iliev; Gregory F Sonnenberg; David Artis
Journal:  Nat Immunol       Date:  2017-07-19       Impact factor: 25.606

Review 4.  Prenatal and postnatal administration of prebiotics and probiotics.

Authors:  Kristin Sohn; Mark A Underwood
Journal:  Semin Fetal Neonatal Med       Date:  2017-07-15       Impact factor: 3.926

5.  Gut microbial metabolites alter IgA immunity in type 1 diabetes.

Authors:  Juan Huang; James A Pearson; Jian Peng; Youjia Hu; Sha Sha; Yanpeng Xing; Gan Huang; Xia Li; Fang Hu; Zhiguo Xie; Yang Xiao; Shuoming Luo; Chen Chao; F Susan Wong; Zhiguang Zhou; Li Wen
Journal:  JCI Insight       Date:  2020-05-21

Review 6.  The potential of the microbiota to influence vaccine responses.

Authors:  David J Lynn; Bali Pulendran
Journal:  J Leukoc Biol       Date:  2017-12-28       Impact factor: 4.962

Review 7.  The CF gastrointestinal microbiome: Structure and clinical impact.

Authors:  Geraint B Rogers; Michael R Narkewicz; Lucas R Hoffman
Journal:  Pediatr Pulmonol       Date:  2016-10

8.  Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of Bacteroides dorei.

Authors:  Anthony D Santilli; Jordan T Russell; Eric W Triplett; Kristi J Whitehead; Daniel C Whitehead
Journal:  Medchemcomm       Date:  2019-07-05       Impact factor: 3.597

Review 9.  Emerging pathogenic links between microbiota and the gut-lung axis.

Authors:  Kurtis F Budden; Shaan L Gellatly; David L A Wood; Matthew A Cooper; Mark Morrison; Philip Hugenholtz; Philip M Hansbro
Journal:  Nat Rev Microbiol       Date:  2016-10-03       Impact factor: 60.633

10.  Structure of the Mucosal and Stool Microbiome in Lynch Syndrome.

Authors:  Yan Yan; David A Drew; Arnold Markowitz; Jason Lloyd-Price; Galeb Abu-Ali; Long H Nguyen; Christina Tran; Daniel C Chung; Katherine K Gilpin; Dana Meixell; Melanie Parziale; Madeline Schuck; Zalak Patel; James M Richter; Peter B Kelsey; Wendy S Garrett; Andrew T Chan; Zsofia K Stadler; Curtis Huttenhower
Journal:  Cell Host Microbe       Date:  2020-04-01       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.